Pınar M. Saip

Istanbul, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

DNA methylation of ANKRD23 as a novel biomarker for early diagnosis of ovarian cancer.

DNA methylation of ANKRD23 as a novel biomarker for early diagnosis of ovarian cancer.

Journal: African journal of reproductive health

Published: August 17, 2026

Blood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer.

Blood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer.

Journal: Molecular biology reports

Published: March 02, 2026

Oncological Outcomes of Breast-Conserving Surgery Versus Mastectomy in Invasive Lobular Breast Cancer: A Single-Center Retrospective Study.

Oncological Outcomes of Breast-Conserving Surgery Versus Mastectomy in Invasive Lobular Breast Cancer: A Single-Center Retrospective Study.

Journal: Medicina (Kaunas, Lithuania)

Published: February 15, 2026

Evaluating Comorbidity Scores in Geriatric Ovarian Cancer: A Retrospective Cohort Analysis.

Evaluating Comorbidity Scores in Geriatric Ovarian Cancer: A Retrospective Cohort Analysis.

Journal: Medicina (Kaunas, Lithuania)

Published: December 22, 2025

CYB5R4 Gene Methylation as a Potential Epigenetic Marker for Ovarian Cancer.

CYB5R4 Gene Methylation as a Potential Epigenetic Marker for Ovarian Cancer.

Journal: Clinical Medicine Insights. Oncology

Published: June 23, 2025

Factors Predicting Additional Residual Nodal Disease With a Metastatic Sentinel Node Biopsy or Targeted Axillary Dissection After Neoadjuvant Chemotherapy.

Factors Predicting Additional Residual Nodal Disease With a Metastatic Sentinel Node Biopsy or Targeted Axillary Dissection After Neoadjuvant Chemotherapy.

Journal: Journal of breast cancer

Published: March 01, 2025

Prognostic value of chemotherapy response score in advanced ovarian cancer: a single-center retrospective analysis.

Prognostic value of chemotherapy response score in advanced ovarian cancer: a single-center retrospective analysis.

Journal: Sao Paulo medical journal = Revista paulista de medicina

Published: January 26, 2025

New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer.

New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer.

Journal: Cancers

Published: May 29, 2024

miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer.

miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer.

Journal: Biochemical genetics

Published: December 02, 2023

Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.

Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.

Journal: Pathology, research and practice

Published: August 25, 2023

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.

Journal: Frontiers in oncology

Published: January 26, 2023

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.

Journal: European journal of breast health

Published: December 12, 2022

Showing 1-12 of 35

Last Updated: 09/26/2026